LY255582_product_DataBase

Bioactivity	LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity[1][2][3][4].
Invitro	LY255582 (40 μM, 24-72 h) 抑制 Huh7 和 MHCC-97H 细胞活力[5]。
In Vivo	LY255582 (100 μg，i.c.v.) 减少大鼠的食物摄入量[1]。LY255582 (15 mg/kg，皮下注射，每日一次) 减少喂食的肥胖 Zucker 大鼠的食物摄入量和体重增加[4]。 Animal Model:
Name	LY255582
CAS	119193-09-8
Formula	C22H35NO2
Molar Mass	345.52
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Levine AS, et al. Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats. Brain Res. 1991 Dec 6;566(1-2):193-7. [2]. Need AB, et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci. 2007 Oct 13;81(17-18):1389-96. [3]. S.L. Gackenheimer, et al. Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: Comparison with the distribution of mu, delta and kappa binding sites. Neuropeptides. 2005. 39 (6), 559-567. [4]. Shaw WN, et al. Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol Biochem Behav. 1993 Nov;46(3):653-9. [5]. Chen DT, et al. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019 Jun;122(6):e157-e167.

PeptideDB

LY255582

CAS: 119193-09-8 F: C22H35NO2 W: 345.52